CNQR has a cult following? Heh, you wouldn't know it by the thread here on SI, maybe I'll have to lurk on the Yahoo thread. Anyway, I should think down here around 3 5/8 (or should I say .625? ) is a good place to buy a first third, maybe a second third in October with one more lousy earnings, and the final batch on the trend back up someday. Seems like if you matched up Concur with something like a Datachannel (another local one to me) you might have a pretty interesting company.
Also in for first thirds of Novel and Informix, just edging out of some of my biotechs into a little software. Also half cash.
Also, I wanted to say something about this...
Rande wrote The usual names apply. . . CRA, PDLI, HGSI, MLNM, MYGN, INCY, GENE, GNSL, GLGC, etc., etc., etc. [this group will soon have more names than the Dot Coms.]
The recent flood of biotech IPOs is part of the reason I've moved out of the sector to some degree--too much damn product (but also to lock in some gains, something I failed to do back in March) But really, isn't every sector drowning in too many names? Maybe what is going to happen is all this new money in biotech will help to gobble up the forgotton names out there--there are a number of biotechs that did not participate in the big biotech funding grab this year--some are some good companies with piles of patents etc. I hope we see buyouts in biotechland, and that is where I still have some money--the orphans and widows. |
